Vagotomy, Truncal
Conditions
Keywords
vagotomy, vagus, GLP-1, Insulin secretion
Brief summary
The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of glucose and Glucagon-like peptide-1 (GLP-1) in respect to insulin secretion. The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous system and for this reason the investigators will research individuals with and without intact nervous supply.
Detailed description
GLP-1 is a potent enterogastron and incretin hormone. It is rapidly inactivated by dipeptidyl peptidase IV so only 10-15% enters the systemic circulation. This has led to the hypothesis that GLP-1 interact locally with afferent sensory nerve fibers. We investigated the role of intact vagal innervations on the effect of glucose and GLP-1 on the insulin secretion
Interventions
DRUGDipeptidyl peptidase 4 (DPP 4) inhibitor
One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
OTHERoral glucose
50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
Sponsors
University of Copenhagen
University Hospital, Gentofte, Copenhagen
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* normal fasting plasma glucose * normal hemoglobin * informed consent
Exclusion criteria
* type 1 diabetes mellitus or type 2 diabetes mellitus * body mass index \> 30 * inflammatory bowel disease * intestinal surgery * serum creatinine \> 250 µM and/or albuminuria * ALAT \> 2 x normal value * Severe cardiac insufficiency * in treatment with medicine which cannot be paused for 12 hours
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| insulin secretion | four hours | The insulin secretion during a four-hour oral glucose tolerance test (OGTT) and an intravenous isoglycaemic clamp is evaluated |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| plasma GIP | 12 time points within four hours | 12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour |
| plasma glucagon | 12 time points within four hours | 12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour |
| plasma GLP-1 | 12 time points within four hours | 12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour |
| plasma GLP-2 | 12 time points within four hours | 12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour |
| plasma PYY | 12 time points within four hours | 12 blood samples will be drawn during the four hours OGTT and intravenous isoglycaemic clamp, most frequently during the first hour |
Countries
Denmark
Outcome results
None listed